Determinants of diagnostic delay in autoimmune atrophic gastritis.


Journal

Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234

Informations de publication

Date de publication:
07 2019
Historique:
received: 08 03 2019
revised: 31 03 2019
accepted: 02 05 2019
pubmed: 23 5 2019
medline: 21 4 2020
entrez: 23 5 2019
Statut: ppublish

Résumé

Autoimmune atrophic gastritis (AAG) is characterised by a wide clinical spectrum that could delay its diagnosis. To quantify the diagnostic delay in patients suffering from AAG and to explore possible risk factors for longer diagnostic delay. Consecutive patients with AAG evaluated at our gastroenterological outpatient clinic between 2009 and 2018 were included. Diagnostic delay was estimated as the time lapse occurring between the appearance of the first likely symptoms, laboratory alterations, and other clues indicative of AAG and the final diagnosis. Patient-dependent and physician-dependent diagnostic delays were also assessed. Multivariable regression models were fitted. 291 patients with AAG (mean age at diagnosis 61 ± 15 years; F:M ratio = 2.3:1) were included. The median overall diagnostic delay was 14 months (interquartile range [IQR] 4-41). Factors associated with longer median overall diagnostic delay were female sex (17 months, IQR 5-48), having a previous misdiagnosis (36 months, IQR 17-125) and a history of infertility/miscarriages (33 months, IQR 8-120), whereas a higher level of education was associated with longer patient-dependent diagnostic delay (4 months, IQR 1-12). First evaluation by a gastroenterologist was associated with a median longer diagnostic delay (6 months, IQR 2-15) compared to an internist (3 months, IQR 3-31) and a haematologist (1 month, IQR 0-2). Age, socioeconomic or marital status did not affect the diagnostic delay. AAG is burdened by substantial diagnostic delay, especially in female patients, and due to lack of awareness, particularly among gastroenterologists. Uncommon vitamin B12 deficiency-related manifestations are overlooked and may prolong the diagnostic delay.

Sections du résumé

BACKGROUND
Autoimmune atrophic gastritis (AAG) is characterised by a wide clinical spectrum that could delay its diagnosis.
AIMS
To quantify the diagnostic delay in patients suffering from AAG and to explore possible risk factors for longer diagnostic delay.
METHODS
Consecutive patients with AAG evaluated at our gastroenterological outpatient clinic between 2009 and 2018 were included. Diagnostic delay was estimated as the time lapse occurring between the appearance of the first likely symptoms, laboratory alterations, and other clues indicative of AAG and the final diagnosis. Patient-dependent and physician-dependent diagnostic delays were also assessed. Multivariable regression models were fitted.
RESULTS
291 patients with AAG (mean age at diagnosis 61 ± 15 years; F:M ratio = 2.3:1) were included. The median overall diagnostic delay was 14 months (interquartile range [IQR] 4-41). Factors associated with longer median overall diagnostic delay were female sex (17 months, IQR 5-48), having a previous misdiagnosis (36 months, IQR 17-125) and a history of infertility/miscarriages (33 months, IQR 8-120), whereas a higher level of education was associated with longer patient-dependent diagnostic delay (4 months, IQR 1-12). First evaluation by a gastroenterologist was associated with a median longer diagnostic delay (6 months, IQR 2-15) compared to an internist (3 months, IQR 3-31) and a haematologist (1 month, IQR 0-2). Age, socioeconomic or marital status did not affect the diagnostic delay.
CONCLUSIONS
AAG is burdened by substantial diagnostic delay, especially in female patients, and due to lack of awareness, particularly among gastroenterologists. Uncommon vitamin B12 deficiency-related manifestations are overlooked and may prolong the diagnostic delay.

Identifiants

pubmed: 31115910
doi: 10.1111/apt.15317
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

167-175

Subventions

Organisme : Italian Society of Internal Medicine
ID : research prize won by Dr. Marco Vincenzo Lenti in 2017
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Auteurs

Marco Vincenzo Lenti (MV)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Emanuela Miceli (E)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Sara Cococcia (S)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Catherine Klersy (C)

Biometry and Clinical Epidemiology, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Martina Staiani (M)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Francesca Guglielmi (F)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Paolo Giuffrida (P)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Alessandro Vanoli (A)

Department of Molecular Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Ombretta Luinetti (O)

Department of Molecular Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Federico De Grazia (F)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Michele Di Stefano (M)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Gino Roberto Corazza (GR)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Antonio Di Sabatino (A)

First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH